Atlas Trials

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

Clinical trial NCT07225816 · RECRUITING

Trial details

NCT number
NCT07225816
Sponsor
Novo Nordisk A/S
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Obesity
Start date
2025-11-07
Primary completion
2026-12-13
Enrollment
71

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.